FDA approves reduced-dose pediatric asthma inhaler
The Food and Drug Administration approved Schering-Plough's Asmanex Twisthaler (mometasone furoate inhalation powder) in a 110-mcg formulation, for preventative asthma therapy for children 4 to 11 years of age....
Recent Videos
Related Content
Pediatric cancer survivors and cardiovascular toxicity, disease risk
March 21st 2025Article
Pediatric cancer survivors can be vulnerable to cardiovascular disease in the short- or long-term with increased recognition of cardiotoxic cancer treatments, as 5-year survival rates for children are greater than 85%.
